Stock Market Reviews

BCRX (BioCryst Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on BCRX (BioCryst Pharmaceuticals, Inc.). Explore the news page 5 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy?
  Madrigal (MDGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Oct 28, 2025 - $BCRX
• BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?
  BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Oct 27, 2025 - $BCRX
• Does BioCryst Stock Offer Value After a 7% Weekly Surge and Rare Disease Optimism?
  If you have been eyeing BioCryst Pharmaceuticals, you are not alone. Whether you are already holding shares or deliberating a new position, recent price swings are giving everyone something to talk about. Over just the past week, BioCryst’s stock jumped by 7.0%, which might feel like a fresh breeze after a bumpier stretch: a 30-day dip of 8.1% and a year-to-date return of -8.2%. Zoom out, though, and there is still that long-term growth story, with the stock up a robust 92.8% over the last...
  Oct 24, 2025 - $BCRX
• BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
  RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) taking place in Orlando, Fla., from November 6-10, 2025. The data will include results from a second interim analysis of the APeX-P trial evaluating long-term prophylaxis with an oral granule formulation of once-daily ORLADEYO® (ber
  Oct 23, 2025 - $BCRX
• BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock?
  BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
  Oct 16, 2025 - $BCRX
• BioCryst to buy Astria Therapeutics for $700m in enterprise value
  Upon completion of the transaction, Astria CEO Jill Milne is set to join BioCryst's board.
  Oct 15, 2025 - $BCRX
• Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX
  ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.
  Oct 15, 2025 - $BCRX